Contact Thank you


At the present time, SR Veterinary Technologies drug-delivery formulations are in various stages of clinical development with on-going trials being planned under strict FDA guidelines.

Although not currently recruiting veterinary practitioners to participate in investigational clinical trials using select SR formulations, we will be conducting future field studies under FDA guidelines as required by 21 CFR 511 regulations under the Food & Drug Act.  
If you are interested in learning more about our future investigational trials, please call: 970.482.0896 or alternatively complete our online form.


Online enquiry for Clinical Trials

Carboplatin SR Chemistry

CarboplatinSR Description CarboplatinSR Dosage CarboplatinSR Chemistry 


Carboplatin [Chemical Name]:
platinum, diammine [1,1-cyclobutane-dicarboxylato (2-)-0,0']-(SP-4-2)


Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties.

It contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.

Carboplatin is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.

These Carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.

This agent possesses tumoricidal activity similar to that of its parent compound, Cisplatin, but is more stable and less toxic. 

Carboplatin SR Datasheet download  

Carboplatin SR Dosage

CarboplatinSR Description CarboplatinSR Dosage CarboplatinSR Chemistry


How Supplied
Carboplatin SR™ is a 100 mg/ml suspension of carboplatin in a patented liquid polymer delivery system. The suspension of drug and polymer system are loaded into 3-cc syringes at volumes of 0.5, 1.0, or 2.0 ml, then capped and placed in a foil-lined package with a 3-cc mixing or re-suspension syringe. The sealed package is then sterilized by gamma irradiation.


DOGS:  For treatment of Canine Osteosarcoma Carboplatin SR™ can be administered to treat dogs with cancer in a dose of 325 mg/m² administered intramuscularly. The polymer releases carboplatin over one month with minimal toxicity. 

CATS:   For treatment of Feline Squamous Cell Carcinoma Carboplatin SR™ is injected intra-tumorally at a dose of 1 mg per cm³ of tumor mass.

Precautions and Contraindications

Carboplatin SR™ is a new animal drug for use only in investigational animals in clinical trials. Not for use in humans.

Unlike Cisplatin, Carboplatin is not emetogenic, and it also can be safely administered to cats (3,4) In cats, neutropenia is the most common complication,with the lowest counts occurring at 14 to 21 days (3) Although not nephrotoxic, carboplatin is excreted by the kidneys and should not be used in an animal with compromised renal function (6,7) 
Carboplatin is myelosuppressive. Neutrophils and platelets are affected in dogs, with the nadir occurring 11 to 14 days after drug administration.


Carboplatin SR Datasheet download   


Dedicated to Improve Treatment Efficacy in Veterinary Medicine 

Following multiple trials reporting effective clinical applications, SR Veterinary Technologies began research and development efforts for several new SR formulations for domestic animal use. The expanding SR Veterinary Technologies portfolio presently includes controlled release formulations for pain management, antibiotic therapy, regulation of reproduction and other indications. 

Read more: Development pipeline